2024-2031年急性肾损伤治疗市场（依产品、损伤、通路及地区）

急性肾损伤治疗市场评估 - 2024-2031

随着肾臟相关疾病的盛行率和认知度不断提高，急性肾损伤 (AKI) 治疗市场正在不断扩大。透析、药物治疗和支持性照护是其中最重要的治疗方法。技术发展和诊断方法的改进都促进了市场的发展。预计到 2024 年，市场规模将超过 15.1 亿美元，到 2031 年将达到 25.6 亿美元。

糖尿病和高血压等慢性疾病的增加推动了急性肾损伤 (AKI) 治疗市场的发展。然而，发展中国家治疗成本的上涨和认知度的低落是阻碍因素。政府的措施、医疗基础设施的改善以及对创新疗法的持续探索，对市场成长至关重要。急性肾损伤治疗需求的不断增长预计将推动市场在2024年至2031年间以6.85%的复合年增长率成长。

急性肾损伤治疗市场定义/概述

急性肾损伤 (AKI) 的治疗包括解决根本病因、维持体液平衡和支持肾功能。这包括药物治疗、必要时进行透析以及监测电解质和废物水平，以预防併发症并促进康復。

急性肾损伤 (AKI) 的治疗重点在于解决根本病因、恢復肾功能并避免併发症。常见的治疗方法包括补液、电解质平衡、药物治疗和透析。早期诊断和治疗对于避免永久性肾损伤和改善患者预后至关重要。

早期发现、个人化治疗方法和再生医学的进步将重塑急性肾损伤 (AKI) 的治疗。基于生物标记的诊断和干细胞疗法等创新预计将透过减缓慢性肾臟病的进展和改善整体肾功能来改善患者的预后。

慢性病的增加是否会推动急性肾损伤治疗市场的成长？

糖尿病和高血压等慢性疾病盛行率的上升是推动急性肾损伤 (美国) 治疗市场发展的主要因素。根据美国疾病管制与预防中心 (CDC) 的数据，美国约有 3,700 万人患有慢性肾臟病(CKD)，而这些疾病通常在早期阶段未被发现。

根据美国肾臟病和肾臟病研究所 (NIDDK) 的数据，5-7% 的住院患者会发生急性肾损伤 (AKI)，高达 20% 的重症患者会发展为急性肾损伤 (AKI)。美国肾臟病学与肾臟病学研究所 (USRDS) 2020 年度数据报告指出，医疗保险受益人群中慢性肾臟病 (CKD) 的盛行率正在上升，美国国家肾臟基金会 (National Kidney Foundation) 也强调了糖尿病和高血压对慢性肾臟病 (CKD) 患者的重大影响。此外，AKI 的盛行率正在急剧上升，凸显了对更优治疗方法的迫切需求。

高昂的治疗费用是否会阻碍急性肾损伤治疗市场的发展？

急性肾损伤 (AKI) 治疗的高昂费用可能会限制市场扩张。根据美国国家医学图书馆发表的一项研究，AKI 患者的平均住院费用为 24,896 美元，而非 AKI 患者的平均住院费用为 13,425 美元。 AKI 额外增加的 11,471 美元费用可能会给个人和医疗保健系统带来沉重的经济负担。

此外，现代诊断和治疗方法的高昂成本可能会阻碍人们获得及时有效的治疗。这种经济限制因素可能会阻碍市场成长，尤其是在医疗资源匮乏、保险覆盖率较低的地区。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查方法

第二章执行摘要

• 主要发现
• 市场概况
• 市集亮点

第三章 市场概况

• 市场规模和成长潜力
• 市场趋势
• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析

第四章急性肾损伤治疗市场（依治疗类型）

• 药物治疗
• 肾臟替代疗法（RRT）

第五章急性肾损伤治疗市场（按原因）

• 肾前性AKI
• 原发性急性肾损伤
• 肾后性急性肾损伤

第六章急性肾损伤治疗市场（依最终使用者）

• 医院和诊所
• 门诊手术中心
• 透析中心

第七章区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯聯合大公国

第八章市场动态

• 市场驱动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第九章 竞争态势

• 主要企业
• 市占率分析

第十章：公司简介

• Baxter International Inc
• Fresenius Medical Care AG & Co KGaA
• B. Braun Melsungen AG
• Angion Biomedica Corp
• AM-Pharma
• Quark Pharmaceuticals Inc
• Asahi Kasei Medical Co Ltd
• LG Chem

第十一章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第十二章 附录

• 简称列表
• 来源和参考文献

Acute Kidney Injury Treatment Market Valuation - 2024-2031

The Acute Kidney Injury (AKI) therapy market is expanding due to rising prevalence of kidney-related illnesses and increasing awareness. Dialysis, medicine and supportive care are among the most important treatments. Technological developments and enhanced diagnostic methods both contribute to market growth. This is likely to enable the market size surpass USD 1.51 Billion valued in 2024 to reach a valuation of around USD 2.56 Billion by 2031.

Rising chronic disorders such as diabetes and hypertension are propelling the AKI therapy market. However, high treatment costs and low awareness in developing countries provide obstacles. Government initiatives and improvements to healthcare infrastructure are critical for market growth, as is continued research into breakthrough therapeutics. The rising demand for acute kidney injury treatment is enabling the market grow at a CAGR of 6.85% from 2024 to 2031.

Acute Kidney Injury Treatment Market: Definition/ Overview

Acute Kidney Injury (AKI) treatment consists of addressing the underlying cause, maintaining fluid balance and supporting kidney function. This involves drugs, dialysis if necessary and monitoring electrolyte and waste levels to avoid problems and enhance recovery.

Acute kidney injury (AKI) treatment focuses on addressing the underlying cause, restoring kidney function and avoiding complications. Common interventions include hydration control, electrolyte balance, medicine and dialysis. Early diagnosis and treatment are critical for avoiding permanent kidney damage and improving patient outcomes.

Advances in early detection, customized therapeutics and regenerative medicine will shape the treatment of Acute Kidney Injury (AKI). Innovations such as biomarker-based diagnostics and stem cell therapies are projected to enhance patient outcomes by slowing the progression of chronic kidney disease and improving overall kidney function.

Will Rising Prevalence of Chronic Diseases Boost the Growth of Acute Kidney Injury Treatment Market?

The rising incidence of chronic disorders including diabetes and hypertension is a major driver driving the acute kidney injury (AKI) therapy market. According to the Centers for Disease Control and Prevention (CDC), around 37 million US individuals have chronic kidney disease (CKD), which is frequently undetected in the early stages.

According to the NIDDK, AKI affects 5-7% of hospitalized patients and up to 20% of critically ill patients acquire AKI. The USRDS 2020 Annual Data Report cites a rise in CKD prevalence among Medicare beneficiaries, while the National Kidney Foundation emphasizes the significant impact of diabetes and hypertension on CKD patients. Furthermore, the prevalence of AKI has increasing dramatically, highlighting the urgent need for better treatments.

Will High Cost of Treatment Hamper the Acute Kidney Injury Treatment Market?

The high cost of treatment for acute kidney injury (AKI) may limit market expansion. A study published in the National Library of Medicine found that the average hospitalization cost for AKI patients is $24,896, compared to $13,425 for individuals without AKI. This $11,471 additional cost associated with AKI may be a considerable financial burden for people and healthcare systems.

Furthermore, the high costs associated with modern diagnostic and therapeutic approaches may impede access to timely and effective care. This economic constraint may hinder market growth, especially in areas with inadequate healthcare resources or insufficient insurance coverage.

Category-Wise Acumens

Will Decreasing Blood Flow to the Kidneys Drive the Injury Segment?

A decrease in blood supply to the kidneys will cause the acute kidney injury (AKI) phase. Reduced renal perfusion is the major cause of AKI, which is frequently caused by severe dehydration, shock, or heart failure. When blood flow is reduced, the kidneys cannot filter waste adequately, resulting in kidney injury. This pathophysiological mechanism contributes significantly to AKI cases, emphasizing the need of targeting decreased renal perfusion in therapeutic efforts.

The growing awareness and emphasis on controlling and avoiding diseases that cause reduced blood flow to the kidneys is expected to fuel growth in the AKI therapy segment. Early detection and intervention are critical for reducing harm and improving patient outcomes, which encourages the development of focused medicines and diagnostic technologies in this area.

Will Increasing Demand for Managing Kidney Failure by Removing Waste Drive the Dialysis Segment?

The dialysis segment will be driven by an increase in demand for waste removal to manage renal failure. As kidney function deteriorates, dialysis becomes necessary to accomplish the crucial job of removing waste and excess fluid from the blood.

The rise in chronic renal disease, diabetes and hypertension, all of which contribute to kidney failure, emphasizes the importance of effective dialysis solutions. Advances in dialysis technology, as well as increasing awareness of its benefits, help to fuel this trend. With an increasing patient population requiring dialysis, driven by the increasing prevalence of kidney failure, demand for dialysis treatments is likely to rise further, propelling innovation and market expansion in this sector.

Country/Region-wise Acumens

Will High Prevalence of Chronic Diseases Drive the Market in North America?

The rising prevalence of chronic diseases will propel the AKI therapy market in North America. Chronic illnesses common in the region, such as diabetes and hypertension, are important risk factors for acute kidney injury. With millions of people impacted by these disorders, there is an increasing demand for better AKI treatments.

North America's modern healthcare system and high level of care encourage the use of novel medicines and technologies to manage and treat AKI. Furthermore, large investments in R&D, together with increasing awareness of kidney health, contribute to market growth. As chronic disease rates rise, the demand for AKI therapies will stay high, fueling market growth in North America.

Will Increasing Awareness of Kidney Diseases Drive the Market in Asia Pacific Region?

The acute kidney injury (AKI) treatment market in Asia-Pacific will grow due to increasing awareness of kidney illnesses. Growing public and healthcare professional awareness of the prevalence, risk factors and implications of kidney disease is resulting in earlier diagnosis and more proactive treatment. This increasing awareness fuels demand for new diagnostic tools and treatment choices.

Furthermore, educational initiatives and government health programs aiming at improving kidney health help to drive market growth. As the public gets more educated about kidney disease prevention and management, there will be a greater uptake of AKI treatments, driving market growth. Improved awareness contributes to the overall development of healthcare infrastructure and encourages investment in medical technologies, increasing regional market growth.

Competitive Landscape

The acute kidney injury treatment market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the acute kidney injury treatment market include:

Baxter International, Inc.

Fresenius Medical Care AG & Co KGaA

Braun Melsungen AG

Angion Biomedica Corp

AM-Pharma

Quark Pharmaceuticals, Inc.

Asahi Kasei Medical Co Ltd

LG Chem

Acute Kidney Injury Treatment Market Latest Developments

In March 2021, B. Braun Avitum AG, a major manufacturer of medical equipment and pharmaceutical products and services and CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat fatal inflammation, announced the partnership launched a global co-marketing agreement to promote the usage of CytoSorb.

In March 2021, Critical Path Institute (C-Path), a nonprofit organization, announced the commencement of the Acute Kidney Injury (AKI) Project in partnership with the US Food and Drug Administration. The business proposes creating prognostic tools to better anticipate and identify drug-induced kidney damage (DIKI).

In November 2020, Vifor Pharma, a Swiss medicine maker, agreed to pay Angion Biomedica up to USD 80.0 Million for rights to experimental kidney drug ANG-3777

Acute Kidney Injury Treatment Market, By Category

• Product:
• Dialysis
• Intermittent Hemodialysis
• Continuous Renal Replacement Therapy (CRRT)
• Sustained Low-Efficiency Dialysis (SLED)
• Drug Therapy
• Antibiotics
• Diuretics
• Immunosuppressive Agents
• Injury:
• Pre-renal Injury
• Intrinsic Renal Injury
• Post-renal Injury
• Distribution Channel:
• Hospitals
• Ambulatory Surgical Centers
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Acute Kidney Injury Treatment Market, By Treatment Type

• Pharmacological Treatment
• Renal Replacement Therapies (RRT)

5. Acute Kidney Injury Treatment Market, By Cause

• Pre-renal AKI
• Intrinsic AKI
• Post-renal AKI

6. Acute Kidney Injury Treatment Market, By End-User

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Dialysis Centers

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Baxter International Inc
• Fresenius Medical Care AG & Co KGaA
• B. Braun Melsungen AG
• Angion Biomedica Corp
• AM-Pharma
• Quark Pharmaceuticals Inc
• Asahi Kasei Medical Co Ltd
• LG Chem

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References